News for Healthier Living

Real-World FLOURISH Study Confirms Osimertinib Benefit in Chinese NSCLC

A large prospective real-world study in China has confirmed that first-line osimertinib provides substantial clinical benefit to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), including those who would have been excluded from pivotal clinical trials. The findings also reveal that patients carrying additional gene co-mutations experience significantly shorter survival, suggesting these individuals may require more intensive treatment approaches.

September 25, 2026


October 2 2026

October 1 2026

September 30 2026

September 29 2026

September 28 2026

September 27 2026

September 25 2026

September 24 2026

September 23 2026

September 22 2026

September 21 2026